In TNBC, smaller tumor size (cT1-2) and carboplatin-containing chemotherapy were significantly linked to pCR, and in HER2-positive cancers, only negative hormone receptor status was predictive for a pCR (Table 3). This evidence concerns the gene NR4A1 and neoplasm.